Monte Rosa Therapeutics (GLUE) Enterprise Value (2023 - 2025)
Historic Enterprise Value for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to -$401.6 million.
- Monte Rosa Therapeutics' Enterprise Value fell 21983.04% to -$401.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$401.6 million, marking a year-over-year decrease of 21983.04%. This contributed to the annual value of -$381.0 million for FY2024, which is 6113.91% down from last year.
- Monte Rosa Therapeutics' Enterprise Value amounted to -$401.6 million in Q3 2025, which was down 21983.04% from -$300.9 million recorded in Q2 2025.
- Monte Rosa Therapeutics' Enterprise Value's 5-year high stood at -$47.0 million during Q2 2023, with a 5-year trough of -$401.6 million in Q3 2025.
- In the last 3 years, Monte Rosa Therapeutics' Enterprise Value had a median value of -$125.6 million in 2024 and averaged -$195.3 million.
- As far as peak fluctuations go, Monte Rosa Therapeutics' Enterprise Value tumbled by 6113.91% in 2024, and later crashed by 23591.41% in 2025.
- Quarter analysis of 3 years shows Monte Rosa Therapeutics' Enterprise Value stood at -$236.4 million in 2023, then plummeted by 61.14% to -$381.0 million in 2024, then decreased by 5.42% to -$401.6 million in 2025.
- Its Enterprise Value stands at -$401.6 million for Q3 2025, versus -$300.9 million for Q2 2025 and -$335.1 million for Q1 2025.